Brazilian Journal of Pain
https://brjp.org.br/article/doi/10.5935/2595-0118.20180045
Brazilian Journal of Pain
Original Article

Prevalence of neuropathic pain in patients with cancer

Prevalência da dor neuropática em pacientes com câncer

Tania Cursino de Menezes Couceiro; Luciana Cavalcanti Lima; Mário Pereira Coutinho Júnior; Pedro Filipe da Luz Siqueira de Oliveira Mello; Thaysi Maria Mendonça Lopes Ferreira; Ana Lígia Pereira Firmino

Downloads: 1
Views: 224

Abstract

BACKGROUND AND OBJECTIVES: To evaluate the prevalence and factors associated with neuropathic pain in cancer patients. 

METHODS: A prospective cross-sectional study conducted from August 2016 to July 2017, with 267 cancer patients above 18 years of age, with pain. Diabetic patients and patients with previous chronic pain unrelated to the current neoplasia were excluded. The demographic and disease information was obtained from the medical records and directly with the patient. The Douleur Neuropathique en 4 questions questionnaire and the numeric pain scale were later applied.

RESULTS: The prevalence of neuropathic pain in the study population was 53%. The average age of patients was 55.3 years. Of the 267 patients, 76% were female. There was no significant difference in the occurrence of neuropathic pain among gender, age, histological type of cancer and type of treatment. Of the patients, 35.5% who underwent chemotherapy had neuropathic pain, and there was no statistical difference between the types of chemotherapy performed. Twenty-four patients who reported pain at the radiotherapy site were diagnosed with neuropathic pain. Of the total, 63 patients who reported pain at the surgical site, 36 were classified with neuropathic pain. An increasing trend of neuropathic pain was observed when treatments were associated. The intensity of this pain was reported as moderate to severe by the majority of patients in the various types of treatment: chemotherapy, radiotherapy, and surgery.

CONCLUSION: When compared to other studies, a high prevalence of neuropathic pain was observed in more than half of the patients evaluated.

Keywords

Chemotherapy, Douleur Neuropathique en 4 questions, Neuropathic pain, Oncologic pain, Pain

Resumo

JUSTIFICATIVA E OBJETIVOS: Avaliar a prevalência e os fatores associados à dor neuropática em pacientes oncológicos.

MÉTODOS: Estudo transversal prospectivo realizado no período de agosto de 2016 a julho de 2017. Participaram 267 pacientes oncológicos maiores de 18 anos que apresentavam dor, e excluídos os pacientes diabéticos e portadores de dor crônica pregressa sem relação com a neoplasia atual. Foram obtidas informações demográficas e sobre a doença no prontuário e diretamente com o paciente. Posteriormente foi aplicado o questionário Douleur Neuropathique en 4 questions e a escala numérica da dor.

RESULTADOS: A prevalência da dor neuropática na população de estudo foi de 53%. A idade média dos pacientes foi 55,3 anos. Dos 267 pacientes, 76% eram do sexo feminino. Não houve diferença significativa de ocorrência de dor neuropática entre os sexos, idade, tipo histológico do câncer e o tipo de tratamento. Dos pacientes, 35,5% que realizaram quimioterapia tinham dor neuropática, não havendo diferença estatística entre os tipos de quimioterapia realizada. Vinte e quatro pacientes que referiam dor no local do tratamento radioterápico apresentaram o diagnóstico de dor neuropática. Do total, 63 pacientes que referiam dor na área cirúrgica, 36 foram classificados com dor neuropática. Observou-se tendência crescente de dor neuropática quando os tratamentos foram associados. A intensidade dessa dor foi referida como moderada a intensa pela maioria dos pacientes nos diversos tipos de tratamento: quimioterapia, radioterapia e cirurgia.

CONCLUSÃO: Quando comparada a outros estudos, foi observada alta prevalência de dor neuropática, em mais da metade dos pacientes avaliados

Palavras-chave

Dor, Dor neuropática, Dor oncológica, Douleur Neuropathique en 4 questionsQuestionnaire, Quimioterapia

References

Goodwin PJ, Hospital MS, Hospital PM, Stockler M. Pain in patients with cancer. Pain Pract. 2014;32(16):413-21.

Wiermann EG, Diz MP, Caponero R, Lages PS, Araujo CZ, Bettega RT. Consenso Brasileiro sobre Manejo da Dor Relacionada ao Câncer. Rev Bras Oncol Clín. 2015;10(38):132-43.

Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol. 2016;16:12.

Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-5.

Miranda CC, Seda Junior LF, Pelloso LR. New physiological classification of pains: current concept of neuropathic pain. Rev Dor. 2016;17(^sSuppl 1):17-9.

Posso IP, Palmeira CC, Vieira ER. Epidemiology of neuropathic pain. Rev Dor. 2016;17(^sSuppl1):11-4.

Everdingen MH van den Beuken-van, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070-90.

Roberto A, Deandrea S, Greco MT, Corli O, Negri E, Pizzuto M. Prevalence of neuropathic pain in cancer patients: pooled estimates from a systematic review of published literature and results from a survey conducted in 50 Italian Palliative Care Centers. J Pain Symptom Manage. 2016;51(6):1091-102.

Pain PP. Persistent pain in cancer survivors: pathogenesis and treatment options. Pain Clin: Up Dates. 2016;XXIV(4):1-8.

Portenoy RK, Dhingra LK. Overview of cancer pain syndromes. UptoDate. 2017.

Boland EG, Ahmedzai SH. Persistent pain in cancer survivors. Curr Opin Support Palliat Care. 2017;11(3):181-90.

Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-35.

Mathieson S, Maher CG, Terwee CB, Campos T Folly De, Lin CW. Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. J Clin Epidemiol. 2015;68(8):957-66.

Carina A, Madeira S, Professora O, Ana D, Herrero m. Aplicação do questionário DN4 no estudo da dor com componente neuropático. 2014.

Oosterling A, Boveldt N te, Verhagen C, Graaf WT van der, Ham M Van, Drift M Van der. Neuropathic pain components in patients with cancer: prevalence, treatment, and interference with daily activities. Pain Pract. 2016;16(4):413-21.

Paiva CJ, Cesse E A. Aspectos relacionados ao atraso no diagnóstico e tratamento do câncer de mama em uma unidade hospitalar de Pernambuco. Rev Bras Cancerol. 2015;61(1):23-30.

Caponero R, Montarroyos ES, Maria S, Tahamtani M. Post-chemotherapy neuropathy. Rev Dor. 2016;17(^sSuppl 1):S56-8.

Paulo S. Prevalência e características da dor neuropática e neuropatia periférica em doentes submetidos à oxaliplatina para tratamento do câncer colorretal. 2016.


Submitted date:
03/07/2018

Accepted date:
07/09/2018

5f1f7a030e88250151dc6779 brjp Articles

BrJP

Share this page
Page Sections